top | item 7108943

(no title)

redofrac | 12 years ago

For human trials of this nature, typically at-risk populations can be used, and it's seen if there's a reduction in infection rates.

discuss

order

icinnamon|12 years ago

Exactly. In this case, we're lucky enough to use an amazing clinic set up in Durban, South Africa, which has a ~15% prevalence rate of HIV.

Robin_Message|12 years ago

This sounds great. I'm genuinely interested, how is the potential vaccine going to be presented to volunteers in Phase I? And do you also deliver a placebo vaccine for blinding?

It seems like believing you are vaccinated would increase risky behaviour. This is bad in itself. It is also bad if the vaccine is only partially effective, since the risk effect might balance the vaccine effect.

With a placebo, knowing you only have a 50/50 chance of getting the actual trial vaccine might also help mitigate the risk effect.

Anyway, just wondering how all this works. Finding an effective vaccine would be fantastic; keep up the good work!